AnaptysBio, Inc. (ANAB) Key Metrics
ANAB valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $1.39B
- Enterprise value
- $1.37B
- P/E (TTM)
- —
- Forward P/E
- 21.0
- PEG ratio
- —
- Price / sales
- 13.1 10-yr median 22.4
- Price / book
- 143.4 10-yr median 2.2
- EV / EBITDA
- 23.4
- Dividend yield
- —
- Beta
- 0.45
ANAB key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsANAB valuation Price multiples at each fiscal year-end price.
Price / sales+57.3%
4.3
2025 · hover or tap a bar for each year
20162025
Price / book+670.1%
27.2
2025 · hover or tap a bar for each year
20162025
Free cash flow yield+56.1 pts
1.9%
2025 · hover or tap a bar for each year
20162025
ANAB returns How much profit the business earns on the capital it uses.
Return on equity+158.2 pts
−24.5%
2025 · hover or tap a bar for each year
20162025
Return on assets+27.9 pts
−3.1%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin+157.0 pts
8.4%
2025 · hover or tap a bar for each year
20162025
Asset turnover+183.7%
0.55
2025 · hover or tap a bar for each year
20162025
ANAB per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+132.7%
$7.49
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$0.42
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
$0.63
2025 · hover or tap a bar for each year
20162025
Book value per share−52.5%
$1.19
2025 · hover or tap a bar for each year
20162025
Shares outstanding+10.4%
31.3M
2025 · hover or tap a bar for each year
20162025
ANAB financial health Debt, liquidity and how easily interest is covered.
Debt / equity−92.7%
0.38
2025 · hover or tap a bar for each year
20162025
Net debt−$281.6M
−$297.5M
2025 · hover or tap a bar for each year
20162025
Current ratio−4.6%
9.07
2025 · hover or tap a bar for each year
20162025
Interest coverage
0.6
2025 · hover or tap a bar for each year
20162025
Debt / assets−94.9%
0.04
2025 · hover or tap a bar for each year
20162025
ANAB efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−37 days
58 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding+583 days
593 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle−620 days
-535 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue−0.4 pts
0.0%
2025 · hover or tap a bar for each year
20162025
ANAB valuation history
Fiscal year-endToday10-year median
ANAB returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ANAB debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ANAB cash returned to shareholders
DividendsBuybacksFree cash flow
ANAB price vs earnings per share
Share price at year-endEPS (right axis)
ANAB key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.01B | $250.5M | $384.5M | $581.9M | $635.5M | $391.3M | $293.1M | $1.05B | $1.33B | — |
| Enterprise value | $715.5M | $234.6M | $11.4M | $160.1M | $108.3M | −$2.0M | −$78.2M | $630.4M | $1.09B | — |
| Price / sales | 4.3 | 2.7 | 22.4 | 56.6 | 10.1 | 5.2 | 36.6 | 209.9 | 132.8 | — |
| Price / book | 27.2 | 3.5 | 4.4 | 2.2 | 1.8 | 1.0 | 0.7 | 2.2 | 4.3 | — |
| Price / free cash flow | 51.7 | — | — | — | — | — | — | — | — | — |
| Price / operating cash flow | 51.4 | — | — | — | — | — | — | — | — | — |
| EV / sales | 3.0 | 2.6 | 0.7 | 15.6 | 1.7 | -0.0 | -9.8 | 126.1 | 109.4 | — |
| EV / EBITDA | 10.3 | — | — | — | — | — | — | — | — | — |
| EV / free cash flow | 36.5 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −1.3% | −58.0% | −42.6% | −22.1% | −9.1% | −5.1% | −33.2% | −5.9% | −2.3% | — |
| Free cash flow yield | 1.9% | −54.2% | −31.6% | −12.7% | −7.4% | −3.8% | −24.0% | −4.7% | −1.5% | — |
| Dividend yield | — | — | 3.0% | — | — | — | — | — | 0.0% | — |
| Shareholder yield (dividends + buybacks) | 6.8% | 0.2% | 16.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Share price at fiscal year-end | $32.32 | $8.83 | $14.28 | $20.66 | $23.17 | $14.33 | $10.83 | $42.53 | $67.15 | — |
| Per share | ||||||||||
| Revenue per share | $7.49 | $3.22 | $0.64 | $0.37 | $2.30 | $2.75 | $0.30 | $0.20 | $0.51 | — |
| Earnings per share | −$0.42 | −$5.12 | −$6.08 | −$4.57 | −$2.11 | −$0.73 | −$3.60 | −$2.50 | −$1.52 | — |
| Operating cash flow per share | $0.63 | −$4.77 | −$4.49 | −$2.61 | −$1.67 | −$0.52 | −$2.57 | −$1.97 | −$0.98 | — |
| Free cash flow per share | $0.63 | −$4.78 | −$4.52 | −$2.63 | −$1.72 | −$0.54 | −$2.60 | −$2.01 | −$1.00 | — |
| Cash per share | $9.94 | $13.58 | $14.52 | $15.67 | $19.98 | $14.42 | $13.83 | $17.31 | $12.56 | — |
| Book value per share | $1.19 | $2.50 | $3.27 | $9.31 | $12.99 | $14.53 | $14.97 | $19.71 | $15.55 | — |
| Tangible book value per share | $1.19 | $2.50 | $3.27 | $9.31 | $12.99 | $14.53 | $14.97 | $19.71 | $15.55 | — |
| Dividends per share | — | — | $0.44 | — | — | — | — | — | $0.00 | — |
| Capex per share | $0.00 | $0.01 | $0.03 | $0.01 | $0.05 | $0.02 | $0.03 | $0.04 | $0.01 | — |
| Debt per share | $0.45 | $13.02 | $0.66 | $0.69 | $0.76 | $0.01 | $0.11 | $0.33 | $0.73 | — |
| Shares outstanding | 31.3M | 28.4M | 26.9M | 28.2M | 27.4M | 27.3M | 27.1M | 24.7M | 19.8M | — |
| Change in shares outstanding | +10.4% | +5.4% | −4.4% | +2.7% | +0.5% | +0.9% | +9.7% | +24.7% | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −24.5% | −182.7% | −93.4% | −41.6% | −15.3% | −5.0% | −21.8% | −15.5% | −17.3% | −10.4% |
| Return on invested capital (ROIC) | — | — | — | — | — | −101.7% | −167.7% | −74.7% | −60.3% | — |
| Return on assets (ROA) | −3.1% | −31.0% | −30.8% | −20.5% | −10.9% | −4.7% | −20.6% | −14.7% | −15.4% | −7.2% |
| Return on tangible assets | −3.6% | −30.0% | −36.2% | −21.1% | −9.0% | −4.8% | −22.4% | −12.1% | −9.1% | −6.8% |
| Free cash flow margin | 8.4% | −148.7% | −708.8% | −718.9% | −74.8% | −19.6% | −879.0% | −991.4% | −197.3% | −54.4% |
| Financial health | ||||||||||
| Total debt | $14.1M | $369.5M | $17.8M | $19.4M | $21.0M | $342,000 | $2.9M | $8.3M | $14.4M | $13.8M |
| Cash & short-term investments | $311.6M | $385.4M | $390.9M | $441.2M | $548.1M | $393.7M | $374.2M | $427.1M | $248.4M | $51.2M |
| Net debt | −$297.5M | −$15.9M | −$373.1M | −$421.8M | −$527.1M | −$393.3M | −$371.3M | −$418.8M | −$234.0M | −$37.4M |
| Debt / equity | 0.38 | 5.21 | 0.20 | 0.07 | 0.06 | 0.00 | 0.01 | 0.02 | 0.05 | 0.35 |
| Debt / assets | 0.04 | 0.76 | 0.04 | 0.03 | 0.03 | 0.00 | 0.01 | 0.02 | 0.04 | 0.22 |
| Net debt / EBITDA | −4.30 | — | — | — | — | — | — | — | — | — |
| Current ratio | 9.07 | 9.51 | 10.87 | 17.16 | 34.40 | 20.01 | 12.79 | 19.89 | 17.93 | 10.20 |
| Quick ratio | 9.07 | 9.51 | 10.87 | 17.16 | 34.40 | 20.01 | 12.79 | 19.89 | 17.93 | 10.20 |
| Interest coverage | 0.6 | -2.3 | -9.1 | -5.5 | -39.2 | -6.0 | -103.2 | -40.4 | -16.2 | -6.6 |
| Working capital | $311.6M | $386.4M | $369.4M | $421.2M | $537.8M | $376.7M | $348.2M | $412.4M | $238.6M | $52.5M |
| Invested capital | −$260.3M | $55.0M | −$285.0M | −$159.7M | −$170.7M | $3.4M | $33.7M | $67.5M | $73.6M | $1.8M |
| Tangible asset value | $37.2M | $70.9M | $88.1M | $262.1M | $356.4M | $396.7M | $405.0M | $486.4M | $307.6M | $39.3M |
| Net current asset value | $23.1M | $18.9M | $42.5M | $98.9M | $267.2M | $376.7M | $347.5M | $411.6M | $230.9M | $35.3M |
| Graham net-net per share | $0.31 | $0.11 | $1.18 | $3.34 | $9.56 | $13.69 | $12.71 | $16.40 | $11.52 | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | $11.7M | — | — | — | — | — | $0 | — |
| Share buybacks (net) | $68.6M | $456,000 | $50.0M | $0 | $0 | $0 | $0 | $0 | $0 | $1,000 |
| Dividends + buybacks / free cash flow | 350.0% | — | — | — | — | — | — | — | — | — |
| Capex / revenue | 0.0% | 0.4% | 4.7% | 3.5% | 2.2% | 0.8% | 10.1% | 21.3% | 2.9% | 0.3% |
| Capex / operating cash flow | 0.4% | — | — | — | — | — | — | — | — | — |
| Capex / depreciation | 0.04 | 0.15 | 0.34 | 0.15 | 0.65 | 1.02 | 1.57 | 3.37 | 1.58 | 0.21 |
| Stock-based compensation / revenue | 15.4% | 37.3% | 193.5% | 265.9% | 24.3% | 15.3% | 155.1% | 199.2% | 43.8% | 7.0% |
| R&D / revenue | 58.0% | 179.5% | 813.8% | 863.2% | 155.9% | 106.7% | 1,241.7% | 1,125.9% | 309.4% | 135.6% |
| SG&A / revenue | 21.6% | 46.4% | 244.5% | 356.2% | 34.0% | 25.1% | 201.2% | 310.5% | 93.4% | 25.7% |
| Efficiency | ||||||||||
| Days sales outstanding | 58.0 | 95.2 | 88.0 | 40.7 | 2.5 | 0.0 | — | 64.8 | 126.7 | 71.9 |
| Days of inventory on hand | — | — | 0.0 | 0.0 | 0.0 | — | — | — | — | 0.0 |
| Days payables outstanding | 593.0 | 9.7 | 10.3 | 9.3 | 11.0 | 46.6 | 39.8 | 25.2 | 28.5 | 45.0 |
| Cash conversion cycle (days) | -534.9 | 85.5 | 77.6 | 31.4 | -8.5 | -46.6 | — | 39.6 | 98.2 | 26.9 |
| Receivables turnover | 6.29 | 3.83 | 4.15 | 8.96 | 144.24 | — | — | 5.63 | 2.88 | 5.08 |
| Payables turnover | 0.62 | 37.66 | 35.36 | 39.25 | 33.06 | 7.82 | 9.16 | 14.47 | 12.80 | 8.12 |
| Inventory turnover | — | — | 132,282,999.00 | 88,798,000.00 | 98,496,000.00 | — | — | — | — | 15,419,000.00 |
| Asset turnover | 0.55 | 0.19 | 0.03 | 0.02 | 0.12 | 0.18 | 0.02 | 0.01 | 0.05 | 0.28 |
| Average receivables | $37.3M | $23.8M | $4.1M | $1.1M | $438,000 | $0 | — | $887,500 | $3.5M | $3.3M |
| Average payables | $3.9M | $4.3M | $3.7M | $2.3M | $3.0M | $10.2M | $10.8M | $3.9M | $2.3M | $1.9M |
| Average inventory | — | — | $1 | $1 | $1 | — | — | — | $0 | $1 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ANAB's annual financial statements (latest annual report filed March 3, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ANAB valuation and financial ratios
AnaptysBio earned a return on equity of −24.5% in fiscal 2025. It ended the year with $14.1 million of debt and $311.6 million in cash and short-term investments, a net cash position of $297.5 million. It returned $68.6 million to shareholders: $0 in dividends and $68.6 million in share buybacks, 350% of free cash flow.
See the ANAB income statement, the ANAB chart for price history, or the ANAB stock overview for the latest quote and news.
ANAB key metrics FAQ
What is AnaptysBio's EV/EBITDA?
AnaptysBio's enterprise value was 10.3 times EBITDA at the end of fiscal 2025 (enterprise value $715.5 million, EBITDA $69.2 million); the current EV/EBITDA is 23.4.
What is AnaptysBio's return on equity?
AnaptysBio's return on equity (ROE) was −24.5% in fiscal 2025: net income of -$13.2 million on average shareholders' equity of $54.0 million.
How much debt does AnaptysBio have?
AnaptysBio had total debt of $14.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.38 and more cash than debt.
Does AnaptysBio buy back its shares?
Yes. AnaptysBio spent $68.6 million on net share repurchases in fiscal 2025 Shares outstanding changed +10.4% over the year, to 31.3M..
What is AnaptysBio's free cash flow yield?
AnaptysBio generated $19.6 million of free cash flow in fiscal 2025, a free cash flow yield of 1.9% on its market value at year-end ($1.0 billion).
What is AnaptysBio's current ratio?
AnaptysBio's current ratio was 9.07 at the end of fiscal 2025: current assets were 9.07 times current liabilities.